Document Detail


Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL) in healthy volunteers.
MedLine Citation:
PMID:  8728349     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Orlistat, a lipase inhibitor, reduces dietary fat absorption, and thus could potentially alter the absorption of some concomitantly administered drugs, such as the nifedipine gastrointestinal therapeutic system (GITS). To assess the effect of orlistat on the bioavailability of nifedipine GITS, a third party-blind, placebo-controlled, randomized, two-way crossover study was performed in 18 healthy volunteers. Each participant received single 60-mg oral doses of nifedipine GITS (Procardia XL; Pfizer Labs, New York, NY) on the fourth day of treatment with 120 mg of orlistat or placebo three times a day for 6 days. The two treatments were separated by a washout period of at least 1 week. Serial blood samples were collected before and at appropriate intervals after each nifedipine dose to determine plasma concentrations of nifedipine. The 90% confidence intervals for the ratio of geometric least-square means for maximum concentration (C(max)) and area under the concentration-time curve (AUCo-t) and for the difference of arithmetic least-square means for time to maximum concentration (t(max)) indicate that the bioavailability of nifedipine was not altered by treatment with orlistat. Therapeutic doses of 120 mg of orlistat three times daily do not significantly alter the bioavailability of a single 60-mg oral dose of nifedipine GITS in healthy volunteers.
Authors:
A T Melia; T E Mulligan; J Zhi
Related Documents :
25066269 - Randomized phase ii open-label study of mfolfox6 in combination with linifanib or bevac...
17236889 - Efficacy and safety of extended release metoprolol succinate in hypertensive children 6...
3886399 - Effects of bay l 5240, a fixed combination of low dose nifedipine and acebutolol on hyp...
8520809 - Metoclopramide blocks bromocriptine induced antihypertensive effect in hypertensive pat...
7720759 - Natriuretic and diuretic effects of felodipine and hydrochlorothiazide after single and...
10202659 - Lower dosages of phentermine-fenfluramine given in the afternoon: five cases with signi...
8816939 - Lack of micronucleus induction by 'sobatum' in bone marrow erythrocytes of swiss mice.
1365649 - Effect of acute and chronic benzodiazepines on plasma gaba in anxious patients and cont...
9649989 - Addition of droperidol to morphine administered by the patient-controlled analgesia met...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  36     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  1996 Apr 
Date Detail:
Created Date:  1996-09-30     Completed Date:  1996-09-30     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  352-5     Citation Subset:  IM    
Affiliation:
Hoffmann-La Roche, Inc., Nutley, New Jersey 07110-1199, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adult
Analysis of Variance
Biological Availability
Calcium Channel Blockers / administration & dosage,  blood,  pharmacokinetics*
Cross-Over Studies
Delayed-Action Preparations
Drug Interactions
Enzyme Inhibitors / pharmacology*
Female
Humans
Hypertension / metabolism
Lactones / pharmacology*
Male
Middle Aged
Nifedipine / administration & dosage,  blood,  pharmacokinetics*
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Delayed-Action Preparations; 0/Enzyme Inhibitors; 0/Lactones; 21829-25-4/Nifedipine; 96829-58-2/orlistat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in po...
Next Document:  Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyri...